论文部分内容阅读
近年来,特别是在2011年,药品生产企业在医改中被推到了风口浪尖。无论是来自社会的诘责,还是来自政策方面施加的压力。企业在承担着生存、经营发展的艰难之外,也承受了它所不堪负载的社会重压。而这一切的背后无法言说的辛酸和苦衷,很多都是不为人们所了解的。本期起,“聚焦企业”栏目将连续刊登“民族制药企业的难事”系列报道,揭开遮掩真相的面纱,真实呈现当前民族制药企业的生存境况,展现他们在改革的夹缝中求生存,在重压下奋发图强的真实现状。
In recent years, especially in 2011, pharmaceutical manufacturers have been pushed to the cusp in medical reform. Whether from social accountability, or from the policy pressure. Enterprises in undertaking the survival, management and development of the hardships, but also bear the burden of social burden it. And the unspeakable bitterness and difficulties behind all these things are not well understood by many people. Since the beginning of this issue, Focus on Businesses will publish a series of articles entitled “Difficulties of Ethnic Pharmaceutical Enterprises” in succession to unveil the veil that veils the truth and truly present the living conditions of the current national pharmaceutical enterprises and show them the gaps in the reform Seek survival, under the pressure of hard work and the true status quo.